TISIDB

Summary
Symbol	FANCA
Name	Fanconi anemia, complementation group A
Aliases	FA-H; FACA; FANCH; Fanconi anemia, complementation group H; Fanconi anemia, type 1; Protein FACA; Fanconi an ......
Chromosomal Location	16q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus. Cytoplasm. Note=The major form is nuclear. The minor form is cytoplasmic.
Domain	PF03511 Fanconi anaemia group A protein PF15865 Fanconi anaemia group A protein N terminus
Function	DNA repair protein that may operate in a postreplication repair or a cell cycle checkpoint function. May be involved in interstrand DNA cross-link repair and in the maintenance of normal chromosome stability.

> Gene Ontology [ TOP ]
Biological Process	GO:0002521 leukocyte differentiation GO:0002694 regulation of leukocyte activation GO:0007126 meiotic nuclear division GO:0007140 male meiosis GO:0007159 leukocyte cell-cell adhesion GO:0007548 sex differentiation GO:0008406 gonad development GO:0008584 male gonad development GO:0008585 female gonad development GO:0022407 regulation of cell-cell adhesion GO:0023035 CD40 signaling pathway GO:0030098 lymphocyte differentiation GO:0030217 T cell differentiation GO:0036297 interstrand cross-link repair GO:0042110 T cell activation GO:0045066 regulatory T cell differentiation GO:0045137 development of primary sexual characteristics GO:0045580 regulation of T cell differentiation GO:0045589 regulation of regulatory T cell differentiation GO:0045619 regulation of lymphocyte differentiation GO:0046545 development of primary female sexual characteristics GO:0046546 development of primary male sexual characteristics GO:0046660 female sex differentiation GO:0046661 male sex differentiation GO:0048608 reproductive structure development GO:0050727 regulation of inflammatory response GO:0050863 regulation of T cell activation GO:0050865 regulation of cell activation GO:0051090 regulation of sequence-specific DNA binding transcription factor activity GO:0051249 regulation of lymphocyte activation GO:0051321 meiotic cell cycle GO:0061458 reproductive system development GO:0070486 leukocyte aggregation GO:0070489 T cell aggregation GO:0071593 lymphocyte aggregation GO:1902105 regulation of leukocyte differentiation GO:1903037 regulation of leukocyte cell-cell adhesion GO:1903046 meiotic cell cycle process GO:1903706 regulation of hemopoiesis GO:2000348 regulation of CD40 signaling pathway
Molecular Function	-
Cellular Component	GO:0043240 Fanconi anaemia nuclear complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa03460 Fanconi anemia pathway
Reactome	R-HSA-73894: DNA Repair R-HSA-6783310: Fanconi Anemia Pathway

Summary
Symbol	FANCA
Name	Fanconi anemia, complementation group A
Aliases	FA-H; FACA; FANCH; Fanconi anemia, complementation group H; Fanconi anemia, type 1; Protein FACA; Fanconi an ......
Chromosomal Location	16q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between FANCA and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between FANCA and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
24501220	Fanconi Anemia	Promote immunity (T cell function)	Here we report that deletion of Fanca or Fancd2 dysregulates the suppressive activity of regulatory T cells (Tregs), shown functionally as exacerbation of graft-vs-host disease (GVHD) in mice. Analysis of CD25(+)Foxp3(+) Tregs indicated that loss of Fanca or Fancd2 dysregulated Foxp3 target gene expression.

Summary
Symbol	FANCA
Name	Fanconi anemia, complementation group A
Aliases	FA-H; FACA; FANCH; Fanconi anemia, complementation group H; Fanconi anemia, type 1; Protein FACA; Fanconi an ......
Chromosomal Location	16q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of FANCA in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	FANCA
Name	Fanconi anemia, complementation group A
Aliases	FA-H; FACA; FANCH; Fanconi anemia, complementation group H; Fanconi anemia, type 1; Protein FACA; Fanconi an ......
Chromosomal Location	16q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of FANCA in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.024	0.925
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.368	0.737
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.235	0.8
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.599	0.058
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.61	0.787
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.59	0.843
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.218	0.486
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.005	0.996
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.587	0.556
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.21	0.867
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.553	0.769
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.381	0.000665

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of FANCA in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	5.9	1.2	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	33.3	-23.3	0.423
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	14.8	5.5	9.3	0.206
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	14.8	6.8	8	0.252
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	22.2	6.2	16	0.53
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	0	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	14.3	10.7	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	FANCA
Name	Fanconi anemia, complementation group A
Aliases	FA-H; FACA; FANCH; Fanconi anemia, complementation group H; Fanconi anemia, type 1; Protein FACA; Fanconi an ......
Chromosomal Location	16q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FANCA. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	FANCA
Name	Fanconi anemia, complementation group A
Aliases	FA-H; FACA; FANCH; Fanconi anemia, complementation group H; Fanconi anemia, type 1; Protein FACA; Fanconi an ......
Chromosomal Location	16q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FANCA. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FANCA. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	FANCA
Name	Fanconi anemia, complementation group A
Aliases	FA-H; FACA; FANCH; Fanconi anemia, complementation group H; Fanconi anemia, type 1; Protein FACA; Fanconi an ......
Chromosomal Location	16q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FANCA. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	FANCA
Name	Fanconi anemia, complementation group A
Aliases	FA-H; FACA; FANCH; Fanconi anemia, complementation group H; Fanconi anemia, type 1; Protein FACA; Fanconi an ......
Chromosomal Location	16q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of FANCA expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	FANCA
Name	Fanconi anemia, complementation group A
Aliases	FA-H; FACA; FANCH; Fanconi anemia, complementation group H; Fanconi anemia, type 1; Protein FACA; Fanconi an ......
Chromosomal Location	16q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between FANCA and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	FANCA
Name	Fanconi anemia, complementation group A
Aliases	FA-H; FACA; FANCH; Fanconi anemia, complementation group H; Fanconi anemia, type 1; Protein FACA; Fanconi an ......
Chromosomal Location	16q24.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting FANCA collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse FANCA